Kyowa Hakko and Daiichi Sankyo acquisitions
of foreign firms total $1.4 billion, signaling that Japanese firms are turning to international M&As for pipeline growth
MDxHealth tapped by Newcastle University, Cancer Research Technology and Pfizer to help develop companion diagnostic for PARP-based ovarian and breast
cancer treatment
Human Genome Sciences Inc. (HGS) and FivePrime Therapeutics Inc. announced March 16 that they have entered into an agreement to develop
and commercialize FivePrime’s FP-1039 product for multiple cancers.
The University of Massachusetts Human Stem Cell Bank and Registry and the United Kingdom Stem Cell Bank on March 15 signed an agreement to share
best practices for stem cell banking and to collaborate on standards for stem cell line characterization, production and distribution in the United States
and U.K.
Technology giant
Hewlett-Packard Development Co. (HP) recently released a drug research application for the company’s inkjet technology that reportedly enables pharmaceutical
companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.
Bristol-Myers Squibb’s newest ‘String
of Pearls’ addition is Chinese outsourcing firm WuXi PharmaTech, which will build a stability testing facility for BMS in China
Quintiles supports Samsung’s entry into the biopharma market through joint venture and makes minority investment in Samsung biosimilars manufacturing
facility
Although ddn’s news coverage spans the global drug discovery industry, we don’t often have occasion to report on Asia-based companies, as
they rarely pursue large-figure mergers and acquisitions.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.